SANDOZ SUNITINIB DIN 02532840
Health Canada record
| Active ingredient(s) | SUNITINIB 12.5 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EX01 SUNITINIB |
| Original market date | 24-May-2023 |
| Current status date | 24-May-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SUNITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02532867 | SANDOZ SUNITINIB | SANDOZ CANADA INCORPORATED | Capsule | SUNITINIB 25 MG | Marketed |
| 02532875 | SANDOZ SUNITINIB | SANDOZ CANADA INCORPORATED | Capsule | SUNITINIB 37.5 MG | Approved |
| 02532883 | SANDOZ SUNITINIB | SANDOZ CANADA INCORPORATED | Capsule | SUNITINIB 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29491 | 2022-11-18 | Abbreviated New Drug Submission (ANDS) |
International API supply for SUNITINIB
9 active FDA Drug Master Files.
Request a quote for SANDOZ SUNITINIB